- Cigna’s adjusted operating EPS for 4Q was $6.79, which was higher than the estimated $6.53.
- Adjusted revenue for the same quarter was $51.15 billion, surpassing the estimated $48.89 billion.
- Cigna’s revenue was $51.11 billion, exceeding the estimate of $48.74 billion.
- The number of global medical customers increased by 9.9% year-on-year to reach 19.78 million, which was higher than the estimated 19.57 million.
- For the year forecast, Cigna anticipates an adjusted operating EPS of at least $28.25, which is slightly lower than the estimated $28.28.
- The company expects adjusted revenue of at least $235.00 billion, which is higher than the estimated $228.24 billion.
- The projected medical care ratio is between 81.7% and 82.7%, which is within the estimated range of 81.9%.
- Cigna anticipates cash flow from operations of at least $11.00 billion, surpassing the estimated $10.63 billion.
- The Board of Directors declared a 14% increase in the quarterly dividend to $1.40 per share.
Cigna Group on Smartkarma
The Cigna Group is generating a lot of buzz on Smartkarma, an independent investment research network, thanks to the recent analyst coverage by Baptista Research. The reports, written by top independent analysts, provide insights into the company’s performance and growth potential. According to Baptista Research, The Cigna Group has exceeded Wall Street’s expectations and is on track for a strong year in 2023. Their health services and benefits platforms continue to show strength, aligning with the company’s mission to effectively serve and grow. In the last quarter, The Cigna Group reported a total revenue of $49 billion and adjusted earnings per share of $6.77, surpassing analyst estimates.
Another report by Baptista Research highlights how innovation and affordability are driving impressive growth for The Cigna Group. The company’s diverse portfolio of companies has led to continued growth, exceeding analyst expectations in revenue and earnings. In the last quarter, The Cigna Group reported total revenues of $48.6 billion, adjusted earnings per share of $6.13, and cash flow from operations of $2.5 billion. The company’s market-leading pharmacy, care, and benefits portfolio at Evernorth Health Services also had a strong quarter, further solidifying The Cigna Group‘s position as a top performer in the industry.
A look at Cigna Group Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
The long-term outlook for Cigna Group looks promising according to the Smartkarma Smart Scores. With an overall score of 3 out of 5, the company is expected to perform well in the coming years. Cigna Group operates as an insurance company, offering various insurance products and services such as life, accident, disability, medicare, and dental insurance. This wide range of offerings allows the company to serve individuals, families, and businesses worldwide.
Cigna Group scored a 3 out of 5 in the categories of value, growth, and resilience, indicating that the company is reasonably priced, has potential for growth, and is resilient in the face of challenges. Additionally, with a score of 4 out of 5 for momentum, the company is showing strong positive momentum in the market. However, Cigna Group received a score of 2 out of 5 in the dividend category, suggesting that it may not be the best option for investors seeking regular dividend payments. Overall, the Smartkarma Smart Scores suggest that Cigna Group is a solid company with a positive outlook for the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
